Contents:
Document Title
Guidelines for the use of subcutaneous parecoxib in palliative patients with cancer pain
Document Date
March 2024
Document Purpose and Intended Audience
This guideline provides information about the use of subcutaneous parecoxib in palliative care patients for cancer pain
Author
Dr Nadia Khan
Consultation Process
Discussed and ratified at SPAGG
Monitoring
This will be audited and reviewed every 3 years
Review Date
(must be within three years)
MArch 2027
Approval Signatures:
SPAGG chair
Dr Jon Tomas
SPAGG secretary
Dr Alice Martin
Date Approved by SPAGG: March 2024
Date submitted to Area Prescribing Committee: N/A
Version History
Version 1
Date
March 2021
Summary of change/ process
N/A
Version 2
Date
March 2024
Summary of change/ process
Reviewed and update by M Aslett
Disclaimer
These Guidelines are intended for use by healthcare professionals and the expectation is that they will use clinical judgement, medical, and nursing knowledge in applying the general principles and recommendations contained within. They are not meant to replace the many available texts on the subject of palliative care.
Some of the management strategies describe the use of drugs outside their licensed indications. They are, however, established and accepted good practice. Please refer to the current BNF for further guidance.
Whilst SPAGG takes every care to compile accurate information , we cannot guarantee its correctness and completeness, and it is subject to change. We do not accept responsibility for any loss, damage or expense resulting from the use of this information.